AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 27783535 — intervention group
Group type: COMPARATOR
Intervention: Negative prime (portraying older individuals as a burden)
Number of subjects: 51
Study 27673363 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum metabolomic profiling
Number of subjects: 380
Study 24732940 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 160
Study 24732940 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine (ASAQ)
Number of subjects: 160
Study 24732940 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine-chlorpheniramine (AQC)
Number of subjects: 160
Study 23773981 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 h of uninterrupted sitting (Sedentary)
Number of subjects: 19
Study 23773981 — intervention group
Group type: COMPARATOR
Intervention: 8 h of sitting interrupted with a 2‐min light‐intensity walk break every 20 min (Breaks)
Number of subjects: 19
Study 23773981 — intervention group
Group type: COMPARATOR
Intervention: 8 h of sitting interrupted with a 2‐min light‐intensity walk break every 20 min and 2×20 min of moderate‐intensity physical activity (Breaks+Physical Activity)
Number of subjects: 19
Study 20221357 — intervention group
Group type: EXPERIMENTAL
Intervention: Student response system used during lecture
Number of subjects: 179
Study 20221357 — intervention group
Group type: COMPARATOR
Intervention: No student response system used during lecture (Control)
Number of subjects: 179
Study 18590223 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative satisfaction rate in patients with BDD
Number of subjects: 0
Study 18590223 — intervention group
Group type: COMPARATOR
Intervention: Postoperative satisfaction rate in patients without BDD
Number of subjects: 0
Study 16637759 — intervention group
Group type: EXPERIMENTAL
Intervention: Envy as a predictor of Schadenfreude when the target is similar in gender to the observer.
Number of subjects: 0
Study 16637759 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 12641480 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with an ACE inhibitor-based blood pressure-lowering regimen (perindopril) with or without indapamide
Number of subjects: 6105
Study 12641480 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 6105
Study 10563643 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 20
Study 10563643 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 20
Study 10563643 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen with codeine
Number of subjects: 20
Study 10563643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8752793 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole stress echocardiography
Number of subjects: 70
Study 8752793 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine stress echocardiography
Number of subjects: 70
Study 8752793 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipyridamole or Dobutamine stress echocardiography
Number of subjects: 70
Study 1998307 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (60-90 mg qid)
Number of subjects: 22
Study 1998307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 6660459 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg metoprolol
Number of subjects: 90
Study 6660459 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg metoprolol
Number of subjects: 90
Study 6660459 — intervention group
Group type: COMPARATOR
Intervention: No metoprolol
Number of subjects: 90
Study 31299810 — intervention group
Group type: EXPERIMENTAL
Intervention: Postintubation TS patients
Number of subjects: 55
Study 28368936 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-controlled intermittent boluses of phenylephrine
Number of subjects: 214
Study 28368936 — intervention group
Group type: COMPARATOR
Intervention: Computer-controlled continuous infusion of phenylephrine
Number of subjects: 214
Study 26245910 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilization intervention (CM)
Number of subjects: 1200
Study 26245910 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1200
Study 24187114 — intervention group
Group type: EXPERIMENTAL
Intervention: Home Visiting (HV)
Number of subjects: 707
Study 24187114 — intervention group
Group type: COMPARATOR
Intervention: Control group (referred to other service providers)
Number of subjects: 707
Study 21896097 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 550 mg once daily for 14 days
Number of subjects: 101
Study 21896097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 18657102 — intervention group
Group type: EXPERIMENTAL
Intervention: Attribute framing in discrete choice experiments (DCE)
Number of subjects: 1920
Study 18657102 — intervention group
Group type: EXPERIMENTAL
Intervention: Accuracy of the test for finding cancer
Number of subjects: 1920
Study 18657102 — intervention group
Group type: EXPERIMENTAL
Intervention: Accuracy of the test for finding large polyps
Number of subjects: 1920
Study 18657102 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing of attributes (e.g., cancers found vs. cancers missed)
Number of subjects: 1920
Study 17366759 — intervention group
Group type: COMPARATOR
Intervention: Conventional toothbrush with horizontal scrubbing (conventional group)
Number of subjects: 37
Study 17366759 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional toothbrush with transverse technique (modified group)
Number of subjects: 37
Study 17366759 — intervention group
Group type: EXPERIMENTAL
Intervention: End‐tufted toothbrush (end‐tufted group)
Number of subjects: 37
Study 15034230 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 12
Study 15034230 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon (10 mg)
Number of subjects: 12
Study 15034230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 11981593 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.125 or 0.25 mg)
Number of subjects: 44
Study 11981593 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 44
Study 11981593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 9534649 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas jet method
Number of subjects: 0
Study 8550169 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic hip screw (DHS)
Number of subjects: 95
Study 8550169 — intervention group
Group type: COMPARATOR
Intervention: Gamma nail
Number of subjects: 95
Study 2197836 — intervention group
Group type: EXPERIMENTAL
Intervention: Drained group (26 patients)
Number of subjects: 50
Study 2197836 — intervention group
Group type: COMPARATOR
Intervention: Undrained group (24 patients)
Number of subjects: 50
Study 2197836 — intervention group
Group type: EXPERIMENTAL
Intervention: Drained group
Number of subjects: 50
Study 2197836 — intervention group
Group type: COMPARATOR
Intervention: Undrained group
Number of subjects: 50
Study 363479 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin 10 mg
Number of subjects: 8
Study 363479 — intervention group
Group type: EXPERIMENTAL
Intervention: mianserin 20 mg
Number of subjects: 8
Study 363479 — intervention group
Group type: EXPERIMENTAL
Intervention: amitriptyline 25 mg
Number of subjects: 8
Study 363479 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 8
Study 7045017 — intervention group
Group type: EXPERIMENTAL
Intervention: viloxazine
Number of subjects: 123
Study 7045017 — intervention group
Group type: COMPARATOR
Intervention: imipramine
Number of subjects: 123
Study 7045017 — intervention group
Group type: COMPARATOR
Intervention: amitriptyline
Number of subjects: 123
Study 7045017 — intervention group
Group type: COMPARATOR
Intervention: doxepin
Number of subjects: 123
Study 7045017 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 123
Study 31182062 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet-based intervention including a screening questionnaire for violence and a video on violence and safety behaviours.
Number of subjects: 0
Study 31182062 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving a video with general information about a healthy and safe pregnancy.
Number of subjects: 0
Study 29926087 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical Behavior Therapy (DBT)
Number of subjects: 173
Study 29926087 — intervention group
Group type: COMPARATOR
Intervention: Individual and Group Supportive Therapy (IGST)
Number of subjects: 173
Study 26528704 — intervention group
Group type: EXPERIMENTAL
Intervention: Reverse trendelenburg position (group 1)
Number of subjects: 146
Study 26528704 — intervention group
Group type: COMPARATOR
Intervention: Routine surgical procedure (group 2)
Number of subjects: 146
Study 25222672 — intervention group
Group type: EXPERIMENTAL
Intervention: GAL021 (high-dose)
Number of subjects: 20
Study 25222672 — intervention group
Group type: COMPARATOR
Intervention: GAL021
Number of subjects: 20
Study 22790614 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 435
Study 22790614 — intervention group
Group type: COMPARATOR
Intervention: Mailed refill reminders
Number of subjects: 435
Study 22790614 — intervention group
Group type: COMPARATOR
Intervention: Illustrated medication schedules
Number of subjects: 435
Study 22790614 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 435
Study 22790614 — intervention group
Group type: EXPERIMENTAL
Intervention: Illustrated medication schedules (post-hoc analysis)
Number of subjects: 435
Study 21162725 — intervention group
Group type: EXPERIMENTAL
Intervention: RBC transfusion
Number of subjects: 500
Study 21162725 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 500
Study 17901854 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block
Number of subjects: 60
Study 17901854 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 60
Study 15327617 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol 400 microg every 3 hours for a maximum of five doses
Number of subjects: 224
Study 15327617 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol 400 microg every 3 hours for a maximum of five doses
Number of subjects: 224
Study 11509481 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated coffee (150 mg caffeine)
Number of subjects: 7
Study 11509481 — intervention group
Group type: COMPARATOR
Intervention: Decaffeinated coffee (<2 mg caffeine)
Number of subjects: 7
Study 9315535 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 217
Study 9315535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 8335138 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic urethrocystopexy (n = 22)
Number of subjects: 36
Study 8335138 — intervention group
Group type: EXPERIMENTAL
Intervention: Pubococcygeal repair (n = 14)
Number of subjects: 36
Study 3523395 — intervention group
Group type: EXPERIMENTAL
Intervention: GSR feedback
Number of subjects: 31
Study 3523395 — intervention group
Group type: COMPARATOR
Intervention: Schultz relaxation
Number of subjects: 31
Study 29105023 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded RME
Number of subjects: 30
Study 29105023 — intervention group
Group type: EXPERIMENTAL
Intervention: Banded RME
Number of subjects: 30
Study 29105023 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 30
Study 26108136 — intervention group
Group type: EXPERIMENTAL
Intervention: PGS with FES
Number of subjects: 5
Study 26108136 — intervention group
Group type: EXPERIMENTAL
Intervention: PGS with TES
Number of subjects: 5
Study 26108136 — intervention group
Group type: COMPARATOR
Intervention: PGS alone
Number of subjects: 5
Study 26108136 — intervention group
Group type: COMPARATOR
Intervention: Strong CPN stimulation (FES) alone
Number of subjects: 5
Study 26108136 — intervention group
Group type: COMPARATOR
Intervention: Weak CPN stimulation (TES) alone
Number of subjects: 5
Study 24572077 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 Gy in two fractions
Number of subjects: 615
Study 24572077 — intervention group
Group type: COMPARATOR
Intervention: 24 Gy in 12 fractions
Number of subjects: 615
Study 21606949 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin dosing strategies (pharmacogenetic dosing)
Number of subjects: 0
Study 21606949 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower target international normalized ratio (INR)
Number of subjects: 0
Study 21606949 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite primary endpoint
Number of subjects: 0
Study 19651954 — intervention group
Group type: EXPERIMENTAL
Intervention: ChloraPrep (2% chlorhexidine gluconate and 70% isopropyl alcohol)
Number of subjects: 150
Study 19651954 — intervention group
Group type: EXPERIMENTAL
Intervention: DuraPrep (0.7% iodophor and 74% isopropyl alcohol)
Number of subjects: 150
Study 19651954 — intervention group
Group type: COMPARATOR
Intervention: povidone-iodine scrub and paint (0.75% iodine scrub and 1.0% iodine paint)
Number of subjects: 150
Study 17456569 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) 0.67 mg/d
Number of subjects: 40
Study 17456569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14735126 — intervention group
Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl (1 mg)
Number of subjects: 24
Study 14735126 — intervention group
Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl (2 mg)
Number of subjects: 24
Study 14735126 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 11472048 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm vein grafts
Number of subjects: 200
Study 11472048 — intervention group
Group type: COMPARATOR
Intervention: Greater saphenous vein grafts
Number of subjects: 200
Study 11472048 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm vein grafts (cephalic vein)
Number of subjects: 200
Study 9973776 — intervention group
Group type: EXPERIMENTAL
Intervention: Kung fu forms protocol (30 sec work, 30 sec rest)
Number of subjects: 18
Study 9973776 — intervention group
Group type: EXPERIMENTAL
Intervention: Kung fu punching protocol (30 sec work, 30 sec rest)
Number of subjects: 18
Study 7821746 — intervention group
Group type: EXPERIMENTAL
Intervention: C-peptide administration
Number of subjects: 0
Study 3062253 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid rotation (change of drugs every 2-3 weeks)
Number of subjects: 109
Study 3062253 — intervention group
Group type: COMPARATOR
Intervention: Slow rotation (change of drugs every 4-6 weeks)
Number of subjects: 109
Study 3062253 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Rapid and Slow rotation)
Number of subjects: 109
Study 3062253 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid rotation arm
Number of subjects: 109
Study 3062253 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with initial white blood count >= 100/nl
Number of subjects: 109
Study 30758417 — intervention group
Group type: EXPERIMENTAL
Intervention: saxagliptin
Number of subjects: 95
Study 30758417 — intervention group
Group type: COMPARATOR
Intervention: glimepiride
Number of subjects: 95
Study 30758417 — intervention group
Group type: COMPARATOR
Intervention: glimepiride combined with polyene phosphatidylcholine
Number of subjects: 95
Study 28583162 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (1 mg/kg daily for 3 weeks)
Number of subjects: 202
Study 28583162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study 26496361 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (25%)
Number of subjects: 104
Study 26496361 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated tucking with oral glucose
Number of subjects: 104
Study 26496361 — intervention group
Group type: COMPARATOR
Intervention: Oral water (placebo)
Number of subjects: 104
Study 26496361 — intervention group
Group type: EXPERIMENTAL
Intervention: Facilitated tucking with oral water
Number of subjects: 104
Study 23369426 — intervention group
Group type: EXPERIMENTAL
Intervention: Both written and oral information modalities
Number of subjects: 140
Study 23369426 — intervention group
Group type: COMPARATOR
Intervention: Written information modality (information sheet)
Number of subjects: 140
Study 23369426 — intervention group
Group type: COMPARATOR
Intervention: Oral information modality (presentation)
Number of subjects: 140
Study 21411805 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision support (CDS) integrated into a computerized prescriber-order-entry (CPOE) system
Number of subjects: 216
Study 21411805 — intervention group
Group type: COMPARATOR
Intervention: Control group with aminoglycoside orders monitored by pharmacists
Number of subjects: 216
Study 19543566 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment
Number of subjects: 4361
Study 19543566 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized treatment of acute bipolar depression
Number of subjects: 4361
Study 19543566 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar depression and refractory relapse prevention
Number of subjects: 4361
Study 17605959 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval walking training
Number of subjects: 246
Study 17605959 — intervention group
Group type: COMPARATOR
Intervention: Moderate-intensity continuous walking training
Number of subjects: 246
Study 15292331 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (1000 mg twice a day)
Number of subjects: 55
Study 15292331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 11199350 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human erythropoietin (12,000 U per week)
Number of subjects: 73
Study 9657323 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycobacterium vaccae immunotherapy
Number of subjects: 35
Study 9657323 — intervention group
Group type: COMPARATOR
Intervention: Placebo (tetanus toxoid)
Number of subjects: 35
Study 8130050 — intervention group
Group type: EXPERIMENTAL
Intervention: flunitrazepam-fentanyl 0.01 mg kg-1 for induction and maintained with flunitrazepam-fentanyl 1.2 mg h-1
Number of subjects: 60
Study 8130050 — intervention group
Group type: COMPARATOR
Intervention: etomidate 0.25 mg kg-1 and fentanyl 0.005 mg kg-1 for induction and 0.6-1.2 vol% isoflurane and fentanyl 1.2 mg h-1 for maintenance
Number of subjects: 60
Study 8130050 — intervention group
Group type: COMPARATOR
Intervention: propofol 4-8 mg kg-1 h-1 and fentanyl 1.2 mg h-1 for maintenance
Number of subjects: 60
Study 2775883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracosactide (D1: 3 mg, D2 and D3: 2 mg/d)
Number of subjects: 102
Study 2775883 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (D1: 240 mg, D2 and D3: 160 mg/d)
Number of subjects: 102
Study 2775883 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracosactide (7 mg for 3 days)
Number of subjects: 102
Study 30427093 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nanocurcumin (120 mg/day)
Number of subjects: 64
Study 30427093 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 28483557 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimalist shoes
Number of subjects: 61
Study 28483557 — intervention group
Group type: COMPARATOR
Intervention: Conventional shoes
Number of subjects: 61
Study 26076828 — intervention group
Group type: EXPERIMENTAL
Intervention: PDL-0101 (1.8 g/d eicosapentaenoic acid; 12 mg/d astaxanthin; 100 mg/d tocopherol-free gamma/delta tocotrienols enriched with geranylgeraniol)
Number of subjects: 102
Study 26076828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 26076828 — intervention group
Group type: EXPERIMENTAL
Intervention: PDL-0101
Number of subjects: 102
Study 23874465 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 454
Study 23874465 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 454
Study 23874465 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention rates at 6 months and 2 years
Number of subjects: 454
Study 23874465 — intervention group
Group type: EXPERIMENTAL
Intervention: Consent to infant blood sample donation
Number of subjects: 454
Study 23874465 — intervention group
Group type: EXPERIMENTAL
Intervention: Interest in probiotics or research
Number of subjects: 454
Study 21751888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group with self-monitoring of blood glucose (SMBG) profiles (six or seven values per day, 3 days/week) and weekly clinic visits
Number of subjects: 63
Study 21751888 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment group
Number of subjects: 63
Study 21751888 — intervention group
Group type: COMPARATOR
Intervention: Control group with glucose profiles and clinic visits at Weeks 0, 6, and 12
Number of subjects: 63
Study 21751888 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 19329498 — intervention group
Group type: EXPERIMENTAL
Intervention: NGAL levels in patients with acute post-MI HF
Number of subjects: 386
Study 19329498 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline NGAL levels in patients with HF following acute MI
Number of subjects: 386
Study 19329498 — intervention group
Group type: EXPERIMENTAL
Intervention: NGAL/lipocalin-2 gene expression in a rat model of post-MI HF
Number of subjects: 386
Study 19329498 — intervention group
Group type: EXPERIMENTAL
Intervention: NGAL immunostaining in cardiomyocytes
Number of subjects: 386
Study 19329498 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-1beta and agonists for toll-like receptors 2 and 4
Number of subjects: 386
Study 16704555 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide 2.5 mg once daily for 6 months
Number of subjects: 37
Study 16704555 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 37
Study 15600124 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation system (group 2)
Number of subjects: 50
Study 15600124 — intervention group
Group type: COMPARATOR
Intervention: No navigation system (group 1)
Number of subjects: 50
Study 11711900 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 40
Study 11711900 — intervention group
Group type: EXPERIMENTAL
Intervention: Arbutamine
Number of subjects: 40
Study 11711900 — intervention group
Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 40